Abbott Earnings Review: Foreign Currency Effects Subdue An Otherwise Strong Operational Growth
Leading healthcare major, Abbott Laboratories (NYSE:ABT) reported its Q1 2016 earnings on April 20, 2016. Despite a strong operating growth, led by the established pharmaceutical division in key emerging markets, Abbott’s key metrics declined year over year due to currency headwinds. The company’s net income and EPS figures were significantly affected by the write down of its assets in Venezuela. Below we analyse Abbott’s performance in Q1 2016:
Notes:
1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Abbott
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)
Relevant Articles
- Should You Pick Abbott Stock At $105 After An Upbeat Q1?
- After Nearly A 20% Rise In Six Months Will Abbott Stock See Higher Levels Post Q1?
- What’s Next For Abbott Stock After A 6% Rise This Year?
- Is Abbott Stock Undervalued At $95?
- Which Is A Better Pick – Abbott Stock Or Amgen?
- Is Abbott Stock A Better Healthcare Pick Over Thermo Fisher Scientific?